Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetesMohammad Alhadj Ali, Colin Dayan, Norkhairin Yusuf et al.|Science Translational Medicine|2017Cited by 215
Referral rates of patients with diabetes to secondary care are inversely related to the prevalence of diabetes in each primary care practice and confidence in treatment, not to HbA1c levelQi Zhuang Siah, Mohammad Alhadj Ali, N.H. Ubeysekara et al.|Primary care diabetes|2021Cited by 4
Proinsulin peptide immunotherapy in type 1 diabetes:safety data of a first in new-onset type 1 diabetes phase 1b trialMohammad Alhadj Ali, Colin M Dayan, Yuk-Fun; id_orcid 0000-0002-8518-8756 Liu et al.|Research Portal (King's College London)|2015Cited by 0